Journal article
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, P Eu, M Michael, Rodney J Hicks
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2014
Abstract
PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. METHODS: A total of 68 patients (39 men; 17 - 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had ..
View full abstractGrants
Funding Acknowledgements
Professor Hicks was the recipient of a translational research grant from the Victorian Cancer Agency, which supported establishment of a prospective database of all patients referred for PRRT. The authors would like to thank the patients, their families and our referring doctors for their trust in and support of our programme, the Unicorn Foundation for its advocacy for NET patients and our NET nurses for their diligence and care of our patients.